Allergan to Acquire MAP Pharmaceuticals

Allergan and MAP Pharmaceuticals have entered into a definitive merger agreement whereby Allergan will acquire 100 percent of the shares of MAP Pharmaceuticals for a price of $25.00 per share. Latham & Watkins advised MAP in the transaction.

DealsNorth AmericaUSBriefs